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Identity 
Other names: DD96; MAP17; RP1-18D14.5; SPAP 




Four coding exons produce a 600 bp transcript only 
expressed in proximal tubule kidney cells. 
PDZK1IP1/MAP17 mRNA is overexpressed in a great 
variety of human carcinomas and strongly correlates 
with tumoral progression (P<0.0001). Many tumor cells 
also express MAP17 and its expression does not 
correlate with expression of SCL (TAL1) a neighbor 
gene reported to be co-expressed in some 
hematopoietic cell lines. SCL neither is expressed in 
most MAP17 positive tumors, indicating the 
independent transcription of MAP17, at least in 
carcinomas. MAP17 promoter is activated by 
oncogenes. 
 
Scheme of the PDZK1IP1/MAP17 locus and transcript. 
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MAP17 is a small, non-glycosylated membrane-
associated protein of 17 kDa, which is located on the 
plasma membrane and the Golgi apparatus. The protein 
sequence possesses a hydrophobic amino-terminus 
containing 13 amino acids that encodes a PDZ-binding 
domain and two transmembrane regions. MAP17 binds 
several PDZ domain-containing proteins, including 
PDZK1, NHERF proteins, NaPiIIa and NHe3. 
Together with NHRF3 and NHRF4, overexpression of 
MAP17 in opossum kidney cells leads to 
internalization of NaPilla to the trans-Golgi network. In 
normal tissue MAP17 is only expressed in the proximal 
tubules of kidney cells. The physiological role of 
MAP17 in proximal tubules is not known, but it 
stimulates specific Na-dependent transport of mannose 
and glucose in Xenopus oocytes and some mammary 
cells. 
Expression 
MAP17 protein is overexpressed in a great variety of 
human carcinomas. Immunohistochemical analysis of 
MAP17 during cancer progression shows, at least in 
prostate and ovarian carcinomas, that overexpression of 
the protein strongly correlates with tumoral progression 
(P<0.0001). Many tumor cells also express MAP17 
protein. 
Localisation 
Apical end of proximal tubule cells in kidney. 
Function 
MAP17 binds several PDZ domain-containing proteins, 
including PDZK1, NHERF proteins, NaPiIIa and 
NHe3. Overexpression of MAP17 into opossum kidney 
cells participates, together with NHRF3 and NHRF4 in 
NaPiIIa internalization to the transgolgi network. The 
physiological role of MAP17 in proximal tubules is not 
known but it stimulates specific Na-dependent transport 
of mannose and glucose in Xenopus oocytes and in 
mammary cells. 
Homology 





Described mutated in malignant mesothelioma tumors 
with a change of aminoacid (T to I). The functional 






Carcinomas of different origin, melanoma, etc. 
Prognosis 
Expression levels increase with stage in most 
carcinomas. 
Oncogenesis 
MAP17 (PDZK1IP1, DD96) enhances tumorigenic 
properties of melanoma cells through ROS increase 
(Guijarro et al., 2007b). Tumor cells that overexpress 
MAP17 show an increased tumoral phenotype with 
enhanced proliferative capabilities both in presence or 
absence of contact inhibition, decreased apoptotic 
sensitivity and increased migration. MAP17-expressing 
clones also grow better in nude mice. The increased 
malignant cell behavior induced by MAP17 are 
associated with an increase in ROS production, and the 
treatment of MAP17-expressing cells with antioxidants 
results in a reduction in the tumorigenic properties of 
these cells. Treatment of melanoma cells with 
inhibitors of Na+-coupled co-transporters lead to an 
inhibition of ROS increase and a decrease in the 
malignant cell behavior in MAP17-expressing clones. 
Finally, we show that MAP17-dependent ROS increase 
and tumorigenesis are dependent on its PDZ-binding 
domain, since disruption of its sequence by point 
mutations abolish its ability to enhance ROS 
production and tumorigenesis. 
At the molecular level MAP17 protects Rat1a 
fibroblasts from Myc-induced apoptosis through ROS-
mediated activation of the PI3K/AKT signalling 
pathway (Guijarro et al., 2007d). A fraction of PTEN  
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undergoes oxidation in MAP17-overexpressing cells. 
Furthermore, activation of AKT by MAP17 as 
measured by Thr308 phosphorylation was independent 
of PI3K activity. Importantly, modulation of ROS by 
antioxidant treatment prevented activation of AKT, 
restoring the level of apoptosis in serum starved Rat1/c-
Myc fibroblasts (Guijarro et al., 2007d). 
MAP17 is overexpressed in a great variety of human 
carcinomas (Guijarro et al., 2007c). 
Immunohistochemical analysis of MAP17 during 
cancer progression shows in prostatic and ovarian 
carcinomas that overexpression of the protein strongly 




Abnormal keratinocyte differentiation. 
In the meta-analysis of public microarray databases for 
different skin diseases, Noh and cols (Noh et al., 2010)  
revealed that MAP17 is commonly up-regulated 
suggesting that may be potentially associated with the 
abnormal keratinocyte differentiation. MAP17 was 
significantly up-regulated in response to interferon-
gamma, interleukin 4 (IL-4), IL-6, IL-17A or IL-22 in 
normal human epidermal keratinocytes (NHEK). 
Interestingly, the PDZK1 gene is localized within the 
atopic dermatitis-linked region on human chromosome 
1q21. In an attempt to evaluate whether MAP17 
regulates the expression of cornified envelope-
associated genes at the 1q21 locus, such as filaggrin, 
loricrin and involucrin, these authors found that the 
over-expression of MAP17 in HaCaT keratinocytes 
significantly decreased the expression of filaggrin, a 
cornified envelope-associated gene. Taken together, the 
Th cell cytokine-induced up-regulation of MAP17 
expression may be linked to the down-regulation of 
filaggrin, which may be associated with the abnormal 
epidermal differentiation observed in the 
dermatological diseases (Noh et al., 2010). 
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